Publications by authors named "S R Joosten-Achjanie"
The current research aimed to define hypothesis-based anti-angiogenic properties of the vascular targeting agent combretastatin A-4 phosphate (combreAp). The in vitro wound assay indicated that combreAp potently inhibited migration of endothelial cells (EC). A significant inhibition of migration could already be measured after 2 hr of treatment.
View Article and Find Full Text PDFPurpose: Tumor stage and nodal status are the most important factors predicting locoregional recurrence in breast cancer. We wanted to investigate the prognostic value of some newer molecular genetic markers for the occurrence of a locoregional recurrence, in order to improve the selection of patients for locoregional adjuvant therapy.
Methods: Bcl-2, p53, MIB-1, pS2 and CD44v6 were determined immunohistochemically on formalin-fixed and paraffin embedded tumour tissues of 163 patients treated by modified radical mastectomy between 1982 and 1987.
Article Synopsis
- The study examines the roles of the bcl-2 proto-oncogene and the p53 tumor suppressor gene in predicting survival outcomes for 345 breast cancer patients over more than 10 years.
- p53 was found to be a significant independent predictor for both overall survival and post-relapse survival, while bcl-2 did not show any prognostic value on its own.
- In patients who were bcl-2 positive, p53 status significantly impacted survival rates, whereas in the bcl-2 negative group, p53 status did not have any prognostic significance.
Article Synopsis
- The study evaluated the prognostic value of the MIB-1 labelling index in 341 primary breast cancer patients, finding a strong correlation with disease-free survival.
- No relationship was identified between MIB-1 labelling and S-phase fraction among 220 patients, indicating that MIB-1 is a more reliable prognostic tool.
- In contrast, while high S-phase fraction showed some link to decreased overall survival, it didn't hold as an independent predictor when other factors were considered.
Article Synopsis
- CD44 is a variable adhesion molecule, with the isoform CD44v6 linked to metastasis and poor outcomes in colon cancer, but research in breast cancer is inconsistent.
- In a study of 338 patients with primary breast tumors, the expression of CD44v6 was assessed, revealing that 64.8% tested positive.
- Despite this high positivity rate, CD44v6 did not show any prognostic value for disease-free or overall survival in breast cancer patients.